Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 12/2007

01-10-2007 | Case Report

Chitotriosidase as a marker of disease activity in sarcoidosis

Authors: Jürgen Brunner, Sabine Scholl-Bürgi, Lothar-Bernd Zimmerhackl

Published in: Rheumatology International | Issue 12/2007

Login to get access

Abstract

Sarcoidosis is a chronic granulomatous inflammation. The clinical spectrum in childhood is heterogeneous. Angiotensin converting enzyme (ACE) activity is used as a marker for disease activity. Human chitotriosidase is produced in macrophages. In this study serum chitotriosidase levels were significantly higher in active sarcoidosis, than in inactive disease or healthy controls. Serum chitotriosidase concentrations may be a useful marker for monitoring disease activity in sarcoidosis.
Literature
1.
Shetty AK, Gedalia A (1998) Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila) 37(12):707–717CrossRef
2.
Brunner J, Sergi C, Muller T, Gassner I, Prufer F, Zimmerhackl LB (2006) Juvenile sarcoidosis presenting as Crohn’s disease. Eur J Pediatr 165:398–401PubMedCrossRef
3.
Ramanan AV, Thimmarayappa AD, Baildam EM (2002) Muscle involvement in childhood sarcoidosis and need for muscle biopsy. Ann Rheum Dis 61(4):376–377PubMedCrossRef
4.
Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM (1995) Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem 270(5):2198–2202PubMedCrossRef
5.
Czartoryska B, Tylki-Szymanska A, Gorska D (1998) Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Clin Biochem 31(5):417–420PubMedCrossRef
6.
Czartoryska B, Tylki-Szymanska A, Lugowska A (2000) Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33(2):147–149PubMedCrossRef
7.
den Tandt WR, van Hoof F (1996) Marked increase of methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase activity in plasma from Gaucher disease patients. J Inherit Metab Dis 19(3):344–350CrossRef
8.
Guo Y, He W, Boer AM, Wevers RA, de Bruijn AM, Groener JE et al (1995) Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J Inherit Metab Dis 18(6):717–722PubMedCrossRef
9.
Michelakakis H, Dimitriou E, Labadaridis I (2004) The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update. J Inherit Metab Dis 27(5):705–706PubMedCrossRef
10.
Allen RK (1991) A review of angiotensin converting enzyme in health and disease. Sarcoidosis 8(2):95–100PubMed
Metadata
Title
Chitotriosidase as a marker of disease activity in sarcoidosis
Authors
Jürgen Brunner
Sabine Scholl-Bürgi
Lothar-Bernd Zimmerhackl
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0363-0

Other articles of this Issue 12/2007

Rheumatology International 12/2007 Go to the issue

Original Article

Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis

Letter to the Editor

Serum chitotriosidase activity in sarcoidosis patients

Letter to the editor

Epidemiological multicenter study on osteoporosis: the EDMUSTO study

Letter to the editor

Chitotriosidase as a marker of disease activity in sarcoidosis

Case Report

Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease

Original Article

Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits